Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.

@article{Juweid1999PredictionOH,
  title={Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.},
  author={Malik E. Juweid and Chuan Huan Zhang and Rosalyn D. Blumenthal and George Hajjar and Robert M Sharkey and David M. Goldenberg},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1999},
  volume={40 10},
  pages={1609-16}
}
UNLABELLED This study was undertaken to determine the factors affecting myelotoxicity after radioimmunotherapy (RAIT) with 131I-labeled anticarcinoembryonic antigen (anti-CEA) monoclonal antibodies (MAbs). METHODS Ninety-nine patients who received 131I-labeled MN-14 or NP-4 anti-CEA MAbs for the treatment of CEA-producing cancers were assessed for platelet and white blood cell (WBC) toxicity based on the common Radiation Therapy Oncology Group (RTOG) criteria. Univariate and multivariate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2010
View 4 Excerpts
Highly Influenced

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

European Journal of Nuclear Medicine and Molecular Imaging • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…